Pharmacists are invited to attend the ‘Confidently answering your patients’ Covid-19 vaccine questions: thrombosis with thrombocytopenia syndrome’ session on Thursday 20 May at APP2021 for an update on the challenges of deploying a new large-scale Covid-19 vaccination program in Australia.
The session will be led by infectious diseases physician, clinical microbiologist and Director of Infectious Diseases at Mater Health Services, Associate Professor Paul Griffin, who is also Medical Director at Nucleus Network (formerly Q-Pharm) where he is the principal investigator on five Covid-19 vaccine clinical trials.
“The clinical update will detail potential vaccine side effects in patients, including the risk of thrombosis with thrombocytopenia syndrome (TTS).
“I hope that community pharmacists can leave my session feeling confident in answering patient’s questions about the Covid-19 vaccine,” he says.
With just over than two weeks until APP2021, pharmacists are encouraged to attend to get the latest Covid-19 vaccine rollout updates firsthand from the leaders in charge of the rollout.
APP Convenor Kos Sclavos adds that Queensland’s Chief Health Officer, Dr Jeannette Young, is among the event’s speakers, and the program features a myriad of vaccination updates, including the promotion and pitfalls of COVAX.
“Vaccine hesitancy is a growing issue and as pharmacists we need to be armed with the facts to support our patients,” he said. “Only at APP will you receive the absolute latest and most up-to-date news.
“I’d hate for any attendees to miss out on these vital updates. If you haven’t already, view the APP program and book your APP2021 registration at appconference.com. See you at APP!”